PATENT CLAIM ANALYSIS

Application Number: 15870276
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["548", "400000"]

Abstract:
The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.

Claim (Index 11):
The method according to  claim 1 , wherein the neurological disease is selected from the group consisting of epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and Alzheimer's disease.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.5
- Patent Class: 548.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15306971', '14353842', '15513357', '13139830', '12663432']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7548169938745453
- 35 USC 102 Novelty (BERT): 0.5496737954353129
- Combined Prediction Score: 0.734302674030622
- Mean Citation Score: 299.658052
- Max Citation Score: 475.04092
- Similarity Product: 230.56794042217496

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test